Agendia

The companies will work together to develop a next-generation sequencing-based kit version of Agendia's molecular breast cancer diagnostics.

The payor has updated its medical policy to state that "the use of MammaPrint is considered medically necessary in women who are diagnosed with primary invasive breast cancer."

Agendia said that the guidelines reflect MammaPrint's rank as the only multigene test to receive level 1A status, based on prospective, randomized data from the MINDACT clinical trial.

The German Association of Gynecological Oncology included the breast cancer diagnostic in its annual update for cancer clinicians.

One group pointed out differences between study group characteristics, while the other wondered about the role of patient preference.

Lebanon-based Cryogene and its subsidiary will distribute the gene expression-based test for breast cancer recurrence in the region.

The MINDACT study of Agendia's MammaPrint has reported that using the tool could cut the use of chemotherapy in half.